EXHIBIT 99.1
Published on May 20, 2019
Exhibit 99.1
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
FRANKLIN LAKES, NJ, May 20, 2019 – Becton, Dickinson and Company
(NYSE: BDX) (the “Company” or “BD”) today announced that it has commenced tender offers to
purchase for cash the debt securities issued by the Company listed in the table below (collectively, the “Securities” and each a “series”).
Up to each Tender SubCap (Not to Exceed the Aggregate Tender Cap)
of the Outstanding Securities of Becton, Dickinson and Company Listed
Below
|
Title of
Security
|
CUSIP Number/
ISIN Number
|
Principal
Amount Outstanding
|
Tender SubCap
|
Acceptance
Priority Level
|
U.S.
Treasury Reference Security |
Bloomberg
Reference
Page
|
Fixed
Spread
|
Early
Tender
Payment
(1)(2)
|
|
5.000%
Notes due
2040
|
075887 AX7;
US075887AX76
|
$300,000,000
|
$75,000,000
|
1
|
3.000% UST
due 2/15/49
|
FIT1
|
+170 bps
|
$30
|
|
4.875%
Notes due
2044
|
075887 BM0;
US075887BM03
|
$299,877,000
|
$75,000,000
|
2
|
3.000% UST
due 2/15/49
|
FIT1
|
+175 bps
|
$30
|
|
4.685%
Notes due
2044
|
075887 BG3;
US075887BG35
|
$1,200,000,000
|
$175,000,000
|
3
|
3.000% UST
due 2/15/49 |
FIT1
|
+145 bps
|
$30
|
|
3.700%
Notes due
2027
|
075887 BW8;
US075887BW84
|
$2,400,000,000
|
$600,000,000
|
4
|
2.375% UST
due 5/15/29
|
FIT1
|
+105 bps
|
$30
|
|
3.734%
Notes due
2024
|
075887 BF5;
US075887BF51
|
$1,375,000,000
|
—
|
5
|
2.250% UST
due 4/30/24
|
FIT1
|
+90 bps
|
$30
|
|
4.669%
Notes due
2047
|
075887 BX6;
US075887BX67
|
$1,500,000,000
|
$100,000,000
|
6
|
3.000% UST
due 2/15/49
|
FIT1
|
+145 bps
|
$30
|
|
2.894%
Notes due
2022
|
075887 BT5;
US075887BT55
|
$1,800,000,000
|
—
|
7
|
2.125% UST
due 5/15/22
|
FIT1
|
+60 bps
|
$30
|
| (1) |
Per $1,000 principal amount.
|
| (2) |
The Total Consideration for Securities validly tendered prior to or at the Early Tender Date (as defined below) and accepted for purchase is calculated using the
applicable Fixed Spread and is inclusive of the Early Tender Payment.
|
The tender offers consist of offers on the terms and conditions set forth
in the offer to purchase, dated May 20, 2019 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), including the offers to purchase for cash in the order of priority set forth in the table above, up to the applicable Tender SubCap, if any, of each of the Company’s 5.000% Notes due 2040, 4.875%
Notes due 2044, 4.685% Notes due 2044, 3.700% Notes due 2027, 3.734% Notes due 2024, 4.669% Notes due 2047 and 2.894% Notes due 2022 (collectively, the “Securities”), subject to an aggregate tender cap of $1,100,000,000 for all tendered series of Securities. The Company reserves
the right, but is under no obligation, to increase any of the Tender SubCaps in the table above or the aggregate tender cap at any time, subject to applicable law. The Company refers investors to the Offer to Purchase for the complete terms and
conditions of the tender offers.
The tender offers for the Securities will expire at 11:59 p.m., New York City time, on June 18, 2019, or, in each
case, any other date and time to which the Company extends the applicable tender offer (such date and time, as it may be extended with respect to a tender offer, the “Expiration
Date”), unless earlier terminated. Holders of Securities must validly tender and not validly withdraw their Securities prior to or at 5:00 p.m., New York City time, on June 3, 2019 (such date and time, as it may be extended with
respect to a tender offer, the “Early Tender Date”), to be eligible to receive the Total Consideration (as defined below), which is inclusive of an amount in cash equal
to the amount set forth in the table above under the heading “Early Tender Payment” (the “Early Tender Payment”). If a holder validly tenders Securities after the
applicable Early Tender Date but prior to or at the applicable Expiration Date, the holder will only be eligible to receive the applicable Late Tender Offer Consideration (as defined below) plus accrued interest.
The applicable consideration (the “Total Consideration”) offered per $1,000 principal amount of each series of Securities validly tendered and accepted for purchase pursuant to the applicable tender offer will be determined in the manner described in the
Offer to Purchase by reference to the applicable fixed spread for such Securities specified in the table above plus the applicable yield based on the bid-side price of the applicable U.S. Treasury Reference Security specified in the table above
at 9:00 a.m., New York City time, on June 4, 2019. The “Late Tender Offer Consideration” is equal to the Total Consideration minus the Early Tender Payment.
The tender offers will expire on the applicable Expiration Date. Except as set forth below,
payment for the Securities that are validly tendered prior to or at the Expiration Date will be made on a date promptly following the Expiration Date, which is currently anticipated to be June 20, 2019, the second business day after the
Expiration Date. The Company reserves the right, in its sole discretion, to make payment for Securities that are validly tendered prior to or at the Early Tender Date on an earlier settlement date, which, if applicable, is currently anticipated
to be June 5, 2019, provided that the conditions to the satisfaction of the applicable tender offer are satisfied.
Holders will also receive accrued and unpaid interest on Securities validly tendered and
accepted for purchase from the applicable last interest payment date up to, but not including, the applicable settlement date.
Tendered Securities may be withdrawn prior to or at, but not after, 5:00 p.m., New York City
time, on June 3, 2019.
The tender offers are subject to the satisfaction or waiver of certain conditions, including a
financing condition, which is specified in the Offer to Purchase. The tender offers are not subject to minimum tender conditions.
Information Relating to the Tender Offers
The Offer to Purchase is being
distributed to holders beginning today. Barclays Capital Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the lead dealer managers for the tender offers.
Investors with questions regarding the tender offers may contact Barclays Capital Inc. at (800) 438-3242 (toll-free) or (212) 528-7581 (collect), Goldman Sachs &
Co. LLC at (800) 828-3182 (toll-free) or (212) 357-0215 (collect) and J.P. Morgan Securities LLC at (866)
834-4666 (toll-free) or (212) 834-8553 (collect). Global Bondholder Services Corporation is the tender and information agent for the tender offers and can be contacted at (866) 794-2200 (toll-free) or (212) 430-3774 (collect).
None of the Company or its affiliates, their respective boards of directors, the dealer managers,
the tender and information agent or the trustee with respect to any Securities is making any recommendation as to whether holders should tender any Securities in response to any of the tender offers, and neither the Company nor any such other
person has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their Securities, and, if so, the principal amount of Securities to tender.
The full details of the tender offers, including complete instructions on how to tender
Securities, are included in the Offer to Purchase. Holders are strongly encouraged to read carefully the Offer to Purchase, including materials incorporated by reference therein, because they will contain important information. The Offer to
Purchase may be downloaded from Global Bondholder Services Corporation’s website at www.gbsc-usa.com/BectonDickinson or obtained from Global Bondholder Services Corporation, free of charge, by calling toll-free at (866) 794-2200 (bankers and
brokers can call collect at (212) 430-3774).
2
About BD
BD is one of the largest global medical technology companies in the world and is advancing the
world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical
therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to
accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the
most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
Contact:
Kristen Cardillo, Communications – (201) 847-5657
Monique N. Dolecki, Investor Relations – (201) 847-5378
Forward-Looking Statements
This press release contains certain estimates and other forward-looking statements (as defined under Federal
securities laws) regarding BD’s performance, including in relation to the consummation of the tender offers. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results
could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These
factors include, but are not limited to: risks relating to the satisfaction of the conditions to the tender offers, including satisfaction of the financing condition, as well as other factors discussed in BD’s filings with the Securities and
Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
# # #
3